Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 14/20 | 1.00 |
| ▸ | KDM5C | P41229 | 8/20 | 1.00 |
| ▸ | KDM5A | P29375 | 7/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 1.00 |
| ▸ | KDM4A | O75164 | 2/20 | 0.78 |
| ▸ | KDM6B | O15054 | 1/20 | 0.78 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.78 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.77 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637431 | 1.00 | KDM5B (1.00) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL19676470 | 0.93 | KDM5B (0.86) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15637682 | 0.92 | KDM5B (0.86) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL18708524 | 0.91 | KDM5B (0.83) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL16291430 | 0.91 | KDM5B (0.83) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL21716673 | 0.90 | KDM5B (0.82) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15637410 | 0.90 | KDM5B (0.81) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL16291798 | 0.90 | KDM5B (0.81) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL19676368 | 0.89 | KDM5B (0.80) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL18286846 | 0.89 | KDM5B (0.80) | KDM5BKDM5CKDM5AKDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | claimed |
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3692152-B1 | METHODS AND COMPOSITIONS FOR ALTERING FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND/OR DOMAINS | BROAD INST INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250215486-A1 | LIVER PROTECTIVE MARC VARIANTS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2025-07-03 | — | — | US | disclosed |
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025085311-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF KMT2D-DEFICIENT CANCERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-3962559-B1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIV HOUSTON SYSTEM (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-12215382-B2 | Liver protective MARC variants and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4058604-A1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| CN-113663076-B | Cancer combination therapy composition | 厦门大学 | 2022-05-13 | — | — | CN | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | KDM5B 344/4885KDM5C 243/4885KDM5A 291/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | KDM5B 4202/4885KDM5C 3315/4885KDM5A 4362/4885 |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | LIPA, LIPE, CEL | KDM5B 1918/4885KDM5C 1839/4885KDM5A 2149/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | KDM5B 4472/4885KDM5C 4439/4885KDM5A 4354/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | KDM5B 4560/4885KDM5C 4362/4885KDM5A 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.